Advertisement


Benjamin D. Smith, MD, on Mastectomy vs Lumpectomy: Complications and Costs

2015 San Antonio Breast Cancer Symposium

Advertisement

Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).



Related Videos

Breast Cancer

Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes

Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).

Breast Cancer

Andrew Seidman, MD, and Erica Mayer, MD, MPH, on Results of the PALLAS Clinical Trial

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract OT1-03-21)

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD: Less is More: Scaling Back Breast Cancer Treatment

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).

Breast Cancer

Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).

Breast Cancer

Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen

Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)

Advertisement

Advertisement




Advertisement